- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.05. | WHO secures 20% funding increase amid US shortfall | ||
| 21.05. | ATS 2025: GSK strengthens argument for twice-annual depemokimab | ||
| 21.05. | BioNTech to invest up to $1.34bn in UK R&D | ||
| 21.05. | FDA to restrict Covid-19 booster doses to older adults | ||
| 20.05. | HHS sets "most favoured nation" pricing targets for drug makers | ||
| 20.05. | China's mAb and ADC licensing was 3xUS's in 2024 - will trade tensions slow it? | ||
| 20.05. | ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care | ||
| 20.05. | ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF | ||
| 20.05. | Skye and Arecor to develop higher formulation of CB1 inhibitor | ||
| 20.05. | London Biotechnology Show Makes Grand Return to Unveil Cutting-edge Advances in Health & Medicine | ||
| 20.05. | Next-Gen Pharma: AI, ML & Digital Twins Converge at AUTOMA+ 2025 | ||
| 20.05. | Pharmaceutical Technology Excellence Awards 2025: Novotech | ||
| 20.05. | Countries formally adopt WHO's Pandemic Agreement for future pandemics | ||
| 20.05. | Japan's MHLW approves GSK's Blenrep combos for multiple myeloma | ||
| 20.05. | ATS 2025: Anti-IL-5 therapy cuts exacerbations in coexisting COPD and asthma patients | ||
| 20.05. | ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF care | ||
| 20.05. | Pfizer signs global licensing deal with 3SBio for bispecific antibody | ||
| 19.05. | Power of collaboration more pertinent than ever says pharma experts | ||
| 19.05. | Regeneron buys bankrupt 23andMe for $256m | ||
| 19.05. | Apnimed to seek approval for sleep apnoea pill after Phase III success | ||
| 19.05. | Five years, one approval: Europe's slow march on Alzheimer's treatments | ||
| 19.05. | FDA approves Incyte's retifanlimab combo for SCAC treatment | ||
| 19.05. | Novo Nordisk's CEO to step down as weight loss market share plummets | ||
| 19.05. | EC approves BMS' perioperative Opdivo and chemo for NSCLC | ||
| 19.05. | BioMarin agrees to acquire Inozyme for $270m |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .